Vanguard Group Portfolio holdings
The Vanguard Group, founded in 1975 by John C. Bogle, is one of the world's largest investment management companies, headquartered in Malvern, Pennsylvania. As of recent years, it manages trillions in assets, offering a wide range of mutual funds, ETFs, and retirement products, catering to both individual and institutional investors. Its philosophy emphasizes low fees, diversification, and a buy-and-hold strategy, making it a dominant player in the passive investing revolution.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.18B |
| 2 |
Medtronic
MDT
|
+$2.06B |
| 3 |
Microsoft
MSFT
|
+$1.61B |
| 4 |
Procter & Gamble
PG
|
+$1.47B |
| 5 |
UBS Group
UBS
|
+$1.01B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.42B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$2.34B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$930M |
| 4 |
Apple
AAPL
|
+$637M |
| 5 |
SWY
SAFEWAY INC
SWY
|
+$620M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 13.67% |
| 2 | Technology | 13.6% |
| 3 | Financials | 13.57% |
| 4 | Industrials | 10.71% |
| 5 | Consumer Discretionary | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3176
McEwen Inc
MUX
$1.17B
| $3.46M | ﹤0.01% |
339,075
+15,199
| +5% | +$170K |
|
|
TRR
3177
DELISTED
Trc Companies
TRR
| $3.46M | ﹤0.01% |
415,416
| – | – |
|
|
TRVN
3178
DELISTED
Trevena, Inc.
TRVN
| $3.45M | ﹤0.01% |
847
+527
| +165% | +$1.93M |
|
|
SURG
3179
DELISTED
SYNERGETICS USA, INC.
SURG
| $3.45M | ﹤0.01% |
639,675
+29,654
| +5% | +$140K |
|
|
CTG
3180
DELISTED
Computer Task Group, Inc.
CTG
| $3.44M | ﹤0.01% |
471,013
+2,422
| +0.5% | +$19.3K |
|
3181
Preformed Line Products
PLPC
$2.22B
| $3.43M | ﹤0.01% |
81,353
+2,995
| +4% | +$141K |
|
|
AST
3182
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $3.43M | ﹤0.01% |
+508,466
| New | +$2.52M |
|
3183
Key Tronic
KTCC
$45.4M
| $3.42M | ﹤0.01% |
317,635
+3,010
| +1% | +$28.5K |
|
|
PHLT
3184
DELISTED
Performant Healthcare Inc
PHLT
| $3.41M | ﹤0.01% |
1,001,949
+108,647
| +12% | +$551K |
|
|
IRD
3185
Opus Genetics
IRD
$300M
| $3.39M | ﹤0.01% |
9,686
+647
| +7% | +$235K |
|
3186
Nature's Sunshine
NATR
$294M
| $3.39M | ﹤0.01% |
258,397
+8,642
| +3% | +$118K |
|
|
SHLO
3187
DELISTED
Shiloh Industries Inc
SHLO
| $3.39M | ﹤0.01% |
241,196
+6,675
| +3% | +$89.1K |
|
|
HALL
3188
DELISTED
Hallmark Financial Services, Inc.
HALL
| $3.38M | ﹤0.01% |
31,854
+1,010
| +3% | +$112K |
|
|
SSRI
3189
DELISTED
Silver Standard Resources
SSRI
| $3.37M | ﹤0.01% |
+743,813
| New | +$4.13M |
|
|
ENZ
3190
DELISTED
Enzo Biochem, Inc.
ENZ
| $3.36M | ﹤0.01% |
1,139,042
+32,076
| +3% | +$105K |
|
3191
Codexis
CDXS
$160M
| $3.36M | ﹤0.01% |
736,523
+28,692
| +4% | +$101K |
|
|
SUM
3192
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $3.32M | ﹤0.01% |
+158,890
| New | +$3.23M |
|
|
IMPR
3193
DELISTED
IMPRIVATA, INC COM
IMPR
| $3.32M | ﹤0.01% |
236,910
+146,081
| +161% | +$2.01M |
|
3194
Iovance Biotherapeutics
IOVA
$2.73B
| $3.31M | ﹤0.01% |
+273,756
| New | +$3.08M |
|
|
CNSY
3195
Cerenome, Inc. Common Stock
CNSY
$26.8M
| $3.31M | ﹤0.01% |
1
| – | – |
|
3196
Research Frontiers
REFR
$17.1M
| $3.3M | ﹤0.01% |
541,555
+4,000
| +0.7% | +$20.8K |
|
3197
LeMaitre Vascular
LMAT
$1.85B
| $3.28M | ﹤0.01% |
391,290
+39,900
| +11% | +$313K |
|
|
LAYN
3198
DELISTED
Layne Christensen Co
LAYN
| $3.28M | ﹤0.01% |
654,572
+36,301
| +6% | +$260K |
|
3199
Cytosorbents Corp
CTSO
$23.3M
| $3.27M | ﹤0.01% |
+248,277
| New | +$2.55M |
|
|
NAME
3200
DELISTED
Rightside Group, Ltd.
NAME
| $3.26M | ﹤0.01% |
321,343
+6,759
| +2% | +$52.2K |
|
Similar funds
Vanguard Group's Q1 2015 Portfolio in Review
As of Q1 2015, Vanguard Group held 4,228 positions worth $1.47T, up 6.2% from $1.39T the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Vanguard Group deployed $66B of net new capital in Q1 2015, opening 181 new positions and adding to 3,456 existing holdings. Its largest new stake was UBS Group: 57,940,325 shares worth $1.09B.
By sector, the portfolio is most concentrated in Healthcare at 14% of assets, up from 13% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Apple, an estimated $637M trimmed.
- Vanguard Group's largest Q1 2015 buy was UBS Group: 57,940,325 shares worth $1.09B.
- Vanguard Group added most to Allergan plc in Q1 2015, an estimated $2.18B increase.
- Vanguard Group's biggest Q1 2015 reduction was Apple, cutting an estimated $637M.
- Vanguard Group fully exited Allergan Inc in Q1 2015, selling an estimated $3.42B.
- Vanguard Group's ten largest holdings make up 12% of its $1.47T portfolio in Q1 2015.
- Vanguard Group opened 181 new positions and closed 75 in Q1 2015.
- Vanguard Group's portfolio value rose 6.2% quarter-over-quarter to $1.47T.
Based on Vanguard Group's 13F filing for Q1 2015, filed 14 May 2015.